Trium Capital LLP Makes New $2.78 Million Investment in Augmedix, Inc. (NASDAQ:AUGX)

Trium Capital LLP purchased a new stake in Augmedix, Inc. (NASDAQ:AUGX - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 1,182,119 shares of the company's stock, valued at approximately $2,778,000. Augmedix accounts for 0.8% of Trium Capital LLP's investment portfolio, making the stock its 24th biggest position. Trium Capital LLP owned 2.41% of Augmedix at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of AUGX. Parkman Healthcare Partners LLC raised its position in Augmedix by 170.1% in the 4th quarter. Parkman Healthcare Partners LLC now owns 1,015,814 shares of the company's stock valued at $5,943,000 after buying an additional 639,732 shares during the last quarter. Ancora Advisors LLC lifted its position in shares of Augmedix by 102.7% in the first quarter. Ancora Advisors LLC now owns 444,660 shares of the company's stock worth $1,819,000 after purchasing an additional 225,330 shares in the last quarter. Hood River Capital Management LLC boosted its holdings in Augmedix by 79.0% during the first quarter. Hood River Capital Management LLC now owns 490,238 shares of the company's stock worth $2,005,000 after purchasing an additional 216,339 shares during the last quarter. Vanguard Group Inc. grew its position in Augmedix by 16.0% in the first quarter. Vanguard Group Inc. now owns 1,302,424 shares of the company's stock valued at $5,327,000 after purchasing an additional 179,534 shares in the last quarter. Finally, Essex Investment Management Co. LLC grew its position in Augmedix by 31.1% in the first quarter. Essex Investment Management Co. LLC now owns 528,985 shares of the company's stock valued at $2,164,000 after purchasing an additional 125,457 shares in the last quarter. 87.11% of the stock is currently owned by institutional investors.

Augmedix Price Performance

Shares of AUGX stock remained flat at $2.35 on Tuesday. Augmedix, Inc. has a 52-week low of $0.73 and a 52-week high of $6.25. The firm has a market cap of $115.07 million, a PE ratio of -5.47 and a beta of -0.22. The stock has a 50-day moving average of $2.31 and a 200-day moving average of $2.10. The company has a quick ratio of 1.66, a current ratio of 1.66 and a debt-to-equity ratio of 1.48.

Augmedix (NASDAQ:AUGX - Get Free Report) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.04). The business had revenue of $13.66 million during the quarter, compared to analyst estimates of $13.68 million. Augmedix had a negative net margin of 46.23% and a negative return on equity of 182.36%. On average, equities research analysts predict that Augmedix, Inc. will post -0.45 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on AUGX shares. William Blair downgraded shares of Augmedix from a "strong-buy" rating to a "hold" rating in a research note on Friday, July 19th. Lake Street Capital reiterated a "hold" rating on shares of Augmedix in a report on Monday, July 22nd. Finally, B. Riley downgraded Augmedix from a "strong-buy" rating to a "hold" rating and decreased their price target for the company from $3.00 to $2.35 in a research note on Friday, July 19th. Four investment analysts have rated the stock with a hold rating, According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $3.09.

About Augmedix

Augmedix, Inc provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits.